tv537248-10q - none - 10.4212986s

Schedule of information regarding reportable segments

Business Segments


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Net sales
Animal Health	$	143,689	$	139,562	$	265,539	$	270,751
Mineral Nutrition		55,685		62,319		108,334		117,157
Performance Products		14,638		16,342		29,859		30,468
Total segments	$	214,012	$	218,223	$	403,732	$	418,376
Depreciation and amortization
Animal Health	$	6,711	$	5,493	$	13,095	$	10,849
Mineral Nutrition		629		616		1,242		1,213
Performance Products		417		279		794		552
Total segments	$	7,757	$	6,388	$	15,131	$	12,614
Adjusted EBITDA
Animal Health	$	33,838	$	35,925	$	58,899	$	71,641
Mineral Nutrition		3,684		4,084		7,159		6,647
Performance Products		1,457		1,514		2,309		2,230
Total segments	$	38,979	$	41,523	$	68,367	$	80,518


Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes	$	16,895	$	20,074	$	20,467	$	42,779
Interest expense, net		3,432		3,015		6,786		5,798
Depreciation and amortization – Total segments		7,757		6,388		15,131		12,614
Depreciation and amortization – Corporate		391		453		798		918
Corporate costs		10,491		9,918		20,219		18,804
Restructure costs		—		—		425		—
Stock-based compensation		564		564		1,129		1,129
Acquisition-related cost of goods sold		—		—		280		—
Acquisition-related transaction costs		—		—		462		—
Acquisition-related other		167		—		167		—
Other, net		—		(1,506)		—		(1,506)
Foreign currency (gains) losses, net		(718)		2,617		2,503		(18)
Adjusted EBITDA – Total segments	$	38,979	$	41,523	$	68,367	$	80,518


	December 31,		June 30,
As of	2019		2019
Identifiable assets
Animal Health	$	572,921	$	508,864
Mineral Nutrition		69,988		67,662
Performance Products		33,530		32,886
Total segments		676,439		609,412
Corporate		111,879		117,259
Total	$	788,318	$	726,671

XML 22 R34.htm IDEA: XBRL DOCUMENT

Acquisition - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Aug. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Aggregate cash consideration		$ 54,549	$ 9,838
Minimum
Business Acquisition [Line Items]
Estimated useful life of definite-lived intangible assets	5 years
Maximum
Business Acquisition [Line Items]
Estimated useful life of definite-lived intangible assets	12 years
Osprey Biotechnics, Inc. ("Osprey")
Business Acquisition [Line Items]
Aggregate cash consideration	$ 54,549
Estimated future payment, liability	7,553
Minimum additional consideration	$ 4,840

XML 23 R38.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Schedule of inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Inventories
Raw materials	$ 73,394	$ 64,441
Work-in-process	10,489	10,699
Finished goods	109,626	123,182
Inventory, net	$ 193,509	$ 198,322

XML 24 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Dec. 31, 2019
Commitments and Contingencies
Commitments and Contingencies	9. Commitments and Contingencies Environmental Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict. While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with, Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance. The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity. The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of Phibro-Tech’s Santa Fe Springs, California facility. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that any groundwater contamination at its site is localized and due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA and RCRA in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. Due to the ongoing nature of the EPA’s investigation, the preliminary stage of the ongoing litigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume. Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be approximately $5,096 and $5,890 at December 31, 2019 and June 30, 2019, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible. Claims and Litigation PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

XML 25 R13.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information

Balance Sheets Additional Information

Balance Sheets-Additional Information

5. Balance Sheets—Additional Information


	December 31,		June 30,
As of	2019		2019
Inventories
Raw materials	$	73,394	$	64,441
Work-in-process		10,489		10,699
Finished goods		109,626		123,182
	$	193,509	$	198,322


	December 31,		June 30,
As of	2019		2019
Goodwill roll-forward
Balance at beginning of period	$	27,348	$	27,348
Osprey acquisition		25,331		—
Balance at end of period	$	52,679	$	27,348


	December 31,		June 30,
As of	2019		2019
Other assets
ROU operating lease assets	$	23,115	$	—
Deferred income taxes		17,039		16,770
Deposits		6,809		7,024
Insurance investments		5,521		5,431
Equity method investments		4,902		4,196
Indemnification asset		3,000		3,000
Deferred financing fees		1,276		1,531
Other		8,216		7,496
	$	69,878	$	45,448


	December 31,		June 30,
As of	2019		2019
Accrued expenses and other current liabilities
Employee related	$	29,845	$	28,298
Current operating lease liabilities		6,672		—
Commissions and rebates		7,942		8,397
Insurance-related		1,291		1,279
Professional fees		5,222		5,212
Income and other taxes		4,791		6,067
Restructuring costs		2,568		3,590
Other		14,840		15,655
	$	73,171	$	68,498


Liability balance at June 30, 2019	$	5,590
Charges		425
Payments		(1,847)
Liability balance at December 31, 2019	$	4,168


	December 31,		June 30,
As of	2019		2019
Other liabilities
Long-term operating lease liabilities	$	17,453	$	—
Long term and deferred income taxes		9,520		8,978
Supplemental retirement benefits, deferred compensation and other		7,837		7,605
Acquisition-related consideration		7,678		—
International retirement plans		5,247		5,133
U.S. pension plan		3,146		3,934
Restructuring costs		1,600		2,000
Other long term liabilities		13,917		15,144
	$	66,398	$	42,794


	December 31,		June 30,
As of	2019		2019
Accumulated other comprehensive income (loss)
Derivative instruments	$	(598)	$	(594)
Foreign currency translation adjustment		(75,845)		(71,225)
Unrecognized net pension gains (losses)		(19,792)		(20,050)
(Provision) benefit for income taxes on derivative instruments		149		148
(Provision) benefit for incomes taxes on long-term intercompany investments		8,166		8,166
(Provision) benefit for income taxes on pension gains (losses)		(2,690)		(2,626)
	$	(90,610)	$	(86,181)

Business Segments - Segments in Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information
Net sales	$ 214,012		$ 218,223	$ 403,732	$ 418,376
Depreciation and amortization	8,148		6,841	15,929	13,532
Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes	16,895		20,074	20,467	42,779
Interest expense, net	3,432		3,015	6,786	5,798
Depreciation and amortization	8,148		6,841	15,929	13,532
Stock-based compensation				1,129	1,129
Acquisition-related costs of goods sold				280
Foreign currency (gains) losses, net	(718)		2,617	2,503	(18)
Identifiable assets	788,318	$ 726,671		788,318
Animal Health
Segment Reporting Information
Net sales	143,689		139,562	265,539	270,751
Reconciliation of income before income taxes to Adjusted EBITDA
Restructure costs		6,281
Mineral Nutrition
Segment Reporting Information
Net sales	55,685		62,319	108,334	117,157
Performance Products
Segment Reporting Information
Net sales	14,638		16,342	29,859	30,468
Operating Segments
Segment Reporting Information
Net sales	214,012		218,223	403,732	418,376
Depreciation and amortization	7,757		6,388	15,131	12,614
Adjusted EBITDA - Total segments	38,979		41,523	68,367	80,518
Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes	16,895		20,074	20,467	42,779
Interest expense, net	3,432		3,015	6,786	5,798
Depreciation and amortization	7,757		6,388	15,131	12,614
Restructure costs				425
Stock-based compensation	564		564	1,129	1,129
Acquisition-related costs of goods sold				280
Acquisition-related transaction costs				462
Acquisition-related other	167			167
Other, net			(1,506)		(1,506)
Foreign currency (gains) losses, net	(718)		2,617	2,503	(18)
Adjusted EBITDA - Total segments	38,979		41,523	68,367	80,518
Identifiable assets	676,439	609,412		676,439
Operating Segments \| Animal Health
Segment Reporting Information
Net sales	143,689		139,562	265,539	270,751
Depreciation and amortization	6,711		5,493	13,095	10,849
Adjusted EBITDA - Total segments	33,838		35,925	58,899	71,641
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	6,711		5,493	13,095	10,849
Adjusted EBITDA - Total segments	33,838		35,925	58,899	71,641
Identifiable assets	572,921	508,864		572,921
Operating Segments \| Mineral Nutrition
Segment Reporting Information
Net sales	55,685		62,319	108,334	117,157
Depreciation and amortization	629		616	1,242	1,213
Adjusted EBITDA - Total segments	3,684		4,084	7,159	6,647
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	629		616	1,242	1,213
Adjusted EBITDA - Total segments	3,684		4,084	7,159	6,647
Identifiable assets	69,988	67,662		69,988
Operating Segments \| Performance Products
Segment Reporting Information
Net sales	14,638		16,342	29,859	30,468
Depreciation and amortization	417		279	794	552
Adjusted EBITDA - Total segments	1,457		1,514	2,309	2,230
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	417		279	794	552
Adjusted EBITDA - Total segments	1,457		1,514	2,309	2,230
Identifiable assets	33,530	32,886		33,530
Corporate
Segment Reporting Information
Depreciation and amortization	391		453	798	918
Reconciliation of income before income taxes to Adjusted EBITDA
Depreciation and amortization	391		453	798	918
Corporate costs	10,491		$ 9,918	20,219	$ 18,804
Identifiable assets	$ 111,879	$ 117,259		$ 111,879

XML 28 R51.htm IDEA: XBRL DOCUMENT

Derivatives - Effects of Derivatives (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Cost of goods sold	$ 144,908	$ 149,579	$ 276,965	$ 283,927
Interest expense, net	3,432	3,015	6,786	5,798
Equity Option \| Cash Flow Hedging \| Brazilian Real puts \| Cost of Sales
Derivative [Line Items]
Gain (loss) recognized in consolidated statements of operations	(63)		(108)	1,084
Equity Option \| Cash Flow Hedging \| Brazilian Real puts \| Other Comprehensive Income (Loss)
Derivative [Line Items]
Gain (loss) recorded in OCI	422	513	59	404
Swap \| Interest Rate Swap \| Cash Flow Hedging \| Other Comprehensive Income (Loss)
Derivative [Line Items]
Gain (loss) recorded in OCI	$ 658	$ (2,756)	$ (63)	$ (2,106)

XML 29 R39.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information - Other balance sheet items (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2019
Goodwill roll-forward
Balance at beginning of period	$ 27,348		$ 27,348
Osprey acquisition			25,331
Balance at end of period		$ 27,348	52,679
Other assets
ROU operating lease assets			23,115
Deferred income taxes		16,770	17,039
Deposits		7,024	6,809
Insurance investments		5,431	5,521
Equity method investments		4,196	4,902
Indemnification asset		3,000	3,000
Deferred financing fees		1,531	1,276
Other		7,496	8,216
Other assets, total		45,448	69,878
Accrued expenses and other current liabilities
Employee related		28,298	29,845
Current operating lease liabilities			6,672
Commissions and rebates		8,397	7,942
Insurance-related		1,279	1,291
Professional fees		5,212	5,222
Income and other taxes		6,067	4,791
Restructuring costs		3,590	2,568
Other		15,655	14,840
Accrued expenses and other current liabilities, total		68,498	73,171
Restructuring Reserve [Roll Forward]
Liability balance at June 30, 2019	5,590		5,590
Charges	$ 425		425
Payments			(1,847)
Liability balance at December 31, 2019		5,590	4,168
Other liabilities
Long-term operating lease liabilities			17,453
Long term and deferred income taxes		8,978	9,520
Supplemental retirement benefits, deferred compensation and other		7,605	7,837
Acquisition-related consideration			7,678
International retirement plans		5,133	5,247
U.S. pension plan		3,934	3,146
Restructuring costs		2,000	1,600
Other long term liabilities		15,144	13,917
Other liabilities, total		42,794	66,398
Accumulated other comprehensive income (loss)
Derivative instruments		(594)	(598)
Foreign currency translation adjustment		(71,225)	(75,845)
Unrecognized net pension gains (losses)		(20,050)	(19,792)
(Provision) benefit for income taxes on derivative instruments		148	149
(Provision) benefit for income taxes on long-term intercompany investments		8,166	8,166
(Provision) benefit for income taxes on pension gains (losses)		(2,626)	(2,690)
Accumulated other comprehensive income (loss)		$ (86,181)	$ (90,610)

XML 30 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Summary of Significant Accounting Policies and New Accounting Standards
Net income	$ 11,894	$ 14,748	$ 14,409	$ 31,062
Weighted average number of shares - basic (in shares)	40,454	40,383	40,454	40,376
Dilutive effect of stock options and restricted stock units	50	140	50	147
Weighted average number of shares - diluted (in shares)	40,504	40,523	40,504	40,523
Net income per share
basic (in dollars per share)	$ 0.29	$ 0.37	$ 0.36	$ 0.77
diluted (in dollars per share)	$ 0.29	$ 0.36	$ 0.36	$ 0.77

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

XML 31 R35.htm IDEA: XBRL DOCUMENT

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Statements of Operations (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Statements Of Operations Additional Information [Line Items]
Total	$ 214,012	$ 218,223	$ 403,732	$ 418,376
United States
Statements Of Operations Additional Information [Line Items]
Total	122,917	126,065	241,404	240,552
Latin America and Canada
Statements Of Operations Additional Information [Line Items]
Total	42,704	40,273	79,445	79,156
Europe, Middle East and Africa
Statements Of Operations Additional Information [Line Items]
Total	27,660	26,186	51,353	51,022
Asia Pacific
Statements Of Operations Additional Information [Line Items]
Total	20,731	25,699	31,530	47,646
Animal Health
Statements Of Operations Additional Information [Line Items]
Total	143,689	139,562	265,539	270,751
Animal Health \| MFAs and other
Statements Of Operations Additional Information [Line Items]
Total	91,955	93,054	166,989	180,058
Animal Health \| Nutritional Specialties
Statements Of Operations Additional Information [Line Items]
Total	33,062	29,460	63,495	56,430
Animal Health \| Vaccines
Statements Of Operations Additional Information [Line Items]
Total	18,672	17,048	35,055	34,263
Mineral Nutrition
Statements Of Operations Additional Information [Line Items]
Total	55,685	62,319	108,334	117,157
Performance Products
Statements Of Operations Additional Information [Line Items]
Total	$ 14,638	$ 16,342	$ 29,859	$ 30,468

XML 32 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended
Related Party Transactions	Dec. 31, 2019
Related Party Transactions
Related Party Transactions	8. Related Party Transactions Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to us as employees or consultants and received aggregate compensation and benefits of approximately $390 and $430 during the three months ended December 31, 2019 and 2018, respectively, and $841 and $1,213 during the six months ended December 31, 2019 and 2018, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

XML 33 R12.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information

Statements of Operations-Additional Information

Statements of Operations-Additional Information

4. Statements of Operations—Additional Information

Animal Health

The Animal Health business develops, manufactures and markets products in three main categories:

Nutritional Specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health.

Mineral Nutrition

Performance Products

The following tables present our revenues disaggregated by major product category and geographic region:

Net Sales by Product Type


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Animal Health
MFAs and other	$	91,955	$	93,054	$	166,989	$	180,058
Nutritional specialties		33,062		29,460		63,495		56,430
Vaccines		18,672		17,048		35,055		34,263
Total Animal Health	$	143,689	$	139,562	$	265,539	$	270,751
Mineral Nutrition		55,685		62,319		108,334		117,157
Performance Products		14,638		16,342		29,859		30,468
Total	$	214,012	$	218,223	$	403,732	$	418,376

Net Sales by Region


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
United States	$	122,917	$	126,065	$	241,404	$	240,552
Latin America and Canada		42,704		40,273		79,445		79,156
Europe, Middle East and Africa		27,660		26,186		51,353		51,022
Asia Pacific		20,731		25,699		31,530		47,646
Total	$	214,012	$	218,223	$	403,732	$	418,376

Net sales by region are based on country of destination.

Interest Expense and Depreciation and Amortization


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Interest expense, net
Term loan	$	2,031	$	2,202	$	4,079	$	4,314
Revolving credit facility		1,530		920		2,961		1,667
Amortization of debt issuance costs and debt discount		221		220		442		441
Acquisition-related accrued interest		79		—		132		—
Other		76		120		156		283
Interest expense		3,937		3,462		7,770		6,705
Interest (income)		(505)		(447)		(984)		(907)
	$	3,432	$	3,015	$	6,786	$	5,798


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Depreciation and amortization
Depreciation of property, plant and equipment	$	5,840	$	5,308	$	11,571	$	10,496
Amortization of intangible assets		2,296		1,521		4,334		3,012
Amortization of other assets		12		12		24		24
	$	8,148	$	6,841	$	15,929	$	13,532

Fair Value Measurements - Changes in fair value of Level 3 liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Business Combination Contingent Consideration Liability [Roll Forward]
Acquisition-related accrued interest	$ (79)	$ 0	$ (132)
Level 3
Business Combination Contingent Consideration Liability [Roll Forward]
Acquisition-related accrued interest			(125)
Balance at December 31, 2019	$ (7,678)		(7,678)
Osprey Biotechnics, Inc. ("Osprey") \| Level 3
Business Combination Contingent Consideration Liability [Roll Forward]
Acquisition			$ (7,553)

XML 36 R50.htm IDEA: XBRL DOCUMENT

Derivatives - Company's Outstanding Derivatives (Details) R$ in Thousands, $ in Thousands	Dec. 31, 2019 BRL (R$)	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Equity Option \| Brazilian Real puts
Derivative [Line Items]
Notional amount \| R$	R$ 108,000
Fair value		$ 659	$ 413
Fair value		(217)	(30)
Swap \| Interest Rate Swap
Derivative [Line Items]
Notional amount		150,000
Swap \| Interest Rate Swap \| Other liabilities
Derivative [Line Items]
Fair value		$ (1,040)	$ (977)

XML 37 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Jun. 30, 2018	$ 4	$ 129,873	$ 131,560	$ (76,483)	$ 184,954
Balance (in shares) at Jun. 30, 2018	40,357,708
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of new revenue standard			1,245		1,245
Comprehensive income (loss)			16,314	(7,195)	9,119
Exercise of stock options		211			211
Exercise of stock options (in shares)	17,860
Dividends declared			(4,037)		(4,037)
Stock-based compensation expense		565			565
Balance at Sep. 30, 2018	$ 4	130,649	145,082	(83,678)	192,057
Balance (in shares) at Sep. 30, 2018	40,375,568
Balance at Jun. 30, 2018	$ 4	129,873	131,560	(76,483)	184,954
Balance (in shares) at Jun. 30, 2018	40,357,708
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)					26,438
Balance at Dec. 31, 2018	$ 4	131,343	154,984	(81,107)	205,224
Balance (in shares) at Dec. 31, 2018	40,386,568
Balance at Sep. 30, 2018	$ 4	130,649	145,082	(83,678)	192,057
Balance (in shares) at Sep. 30, 2018	40,375,568
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)			14,748	2,571	17,319
Exercise of stock options		130			130
Exercise of stock options (in shares)	11,000
Dividends declared			(4,846)		(4,846)
Stock-based compensation expense		564			564
Balance at Dec. 31, 2018	$ 4	131,343	154,984	(81,107)	205,224
Balance (in shares) at Dec. 31, 2018	40,386,568
Balance at Jun. 30, 2019	$ 4	133,266	168,926	(86,181)	216,015
Balance (in shares) at Jun. 30, 2019	40,453,608
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)			2,515	(7,547)	(5,032)
Dividends declared			(4,854)		(4,854)
Stock-based compensation expense		565			565
Balance at Sep. 30, 2019	$ 4	133,831	166,587	(93,728)	206,694
Balance (in shares) at Sep. 30, 2019	40,453,608
Balance at Jun. 30, 2019	$ 4	133,266	168,926	(86,181)	216,015
Balance (in shares) at Jun. 30, 2019	40,453,608
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)					9,980
Balance at Dec. 31, 2019	$ 4	134,395	173,626	(90,610)	217,415
Balance (in shares) at Dec. 31, 2019	40,453,608
Balance at Sep. 30, 2019	$ 4	133,831	166,587	(93,728)	206,694
Balance (in shares) at Sep. 30, 2019	40,453,608
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)			11,894	3,118	15,012
Dividends declared			(4,855)		(4,855)
Stock-based compensation expense		564			564
Balance at Dec. 31, 2019	$ 4	$ 134,395	$ 173,626	$ (90,610)	$ 217,415
Balance (in shares) at Dec. 31, 2019	40,453,608

XML 38 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 11,894	$ 14,748	$ 14,409	$ 31,062
Change in fair value of derivative instruments	1,080	(2,243)	(4)	(1,702)
Foreign currency translation adjustment	2,203	4,163	(4,620)	(3,519)
Unrecognized net pension gains (losses)	138	124	258	232
(Provision) benefit for income taxes	(303)	527	(63)	365
Other comprehensive income (loss)	3,118	2,571	(4,429)	(4,624)
Comprehensive income (loss)	$ 15,012	$ 17,319	$ 9,980	$ 26,438

XML 39 R49.htm IDEA: XBRL DOCUMENT

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Commitments and Contingencies - Additional Information (Details) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2019 USD ($) item	Jun. 30, 2019 USD ($)
Commitments And Contingencies [Line Items]
Number of potentially responsible parties \| item	140
Current And Long Term Liabilities
Commitments And Contingencies [Line Items]
Accrual for environmental loss contingencies payments \| $	$ 5,096	$ 5,890

XML 40 R41.htm IDEA: XBRL DOCUMENT

Debt - Summary of long-term debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Debt
Term A Loan due June 2022	$ 225,000	$ 231,250
Other		40
Long-term debt including current maturities	225,000	231,290
Unamortized debt issuance costs and debt discount	(929)	(1,115)
Long-term debt after debt issuance costs	224,071	230,175
Less: current maturities	(15,625)	(12,540)
Long-term debt	$ 208,446	$ 217,635

XML 41 R45.htm IDEA: XBRL DOCUMENT

Leases - Other supplemental information (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)
Leases
Operating cash flows used for ROU operating leases	$ 1,968	$ 3,645
Right of use assets obtained in exchange for new operating lease liabilities (non-cash)	$ 3,972	$ 7,762
Weighted average remaining lease term (in years) - ROU operating leases	6 years 4 months 24 days	6 years 4 months 24 days
Weighted average discount rate - ROU operating leases	4.17%	4.17%

XML 42 R24.htm IDEA: XBRL DOCUMENT

Statements of Operations-Additional Information (Tables)

Statements of Operations-Additional Information

Schedule of revenues disaggregated by major product category and geographic region

Net Sales by Product Type


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Animal Health
MFAs and other	$	91,955	$	93,054	$	166,989	$	180,058
Nutritional specialties		33,062		29,460		63,495		56,430
Vaccines		18,672		17,048		35,055		34,263
Total Animal Health	$	143,689	$	139,562	$	265,539	$	270,751
Mineral Nutrition		55,685		62,319		108,334		117,157
Performance Products		14,638		16,342		29,859		30,468
Total	$	214,012	$	218,223	$	403,732	$	418,376

Net Sales by Region


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
United States	$	122,917	$	126,065	$	241,404	$	240,552
Latin America and Canada		42,704		40,273		79,445		79,156
Europe, Middle East and Africa		27,660		26,186		51,353		51,022
Asia Pacific		20,731		25,699		31,530		47,646
Total	$	214,012	$	218,223	$	403,732	$	418,376

Schedule of additional information of statements of operations


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Interest expense, net
Term loan	$	2,031	$	2,202	$	4,079	$	4,314
Revolving credit facility		1,530		920		2,961		1,667
Amortization of debt issuance costs and debt discount		221		220		442		441
Acquisition-related accrued interest		79		—		132		—
Other		76		120		156		283
Interest expense		3,937		3,462		7,770		6,705
Interest (income)		(505)		(447)		(984)		(907)
	$	3,432	$	3,015	$	6,786	$	5,798


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Depreciation and amortization
Depreciation of property, plant and equipment	$	5,840	$	5,308	$	11,571	$	10,496
Amortization of intangible assets		2,296		1,521		4,334		3,012
Amortization of other assets		12		12		24		24
	$	8,148	$	6,841	$	15,929	$	13,532

XML 43 R20.htm IDEA: XBRL DOCUMENT

Business Segments

XML 44 R28.htm IDEA: XBRL DOCUMENT

Business Segments

Business Segments

12. Business Segments

The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Net sales
Animal Health	$	143,689	$	139,562	$	265,539	$	270,751
Mineral Nutrition		55,685		62,319		108,334		117,157
Performance Products		14,638		16,342		29,859		30,468
Total segments	$	214,012	$	218,223	$	403,732	$	418,376
Depreciation and amortization
Animal Health	$	6,711	$	5,493	$	13,095	$	10,849
Mineral Nutrition		629		616		1,242		1,213
Performance Products		417		279		794		552
Total segments	$	7,757	$	6,388	$	15,131	$	12,614
Adjusted EBITDA
Animal Health	$	33,838	$	35,925	$	58,899	$	71,641
Mineral Nutrition		3,684		4,084		7,159		6,647
Performance Products		1,457		1,514		2,309		2,230
Total segments	$	38,979	$	41,523	$	68,367	$	80,518


Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes	$	16,895	$	20,074	$	20,467	$	42,779
Interest expense, net		3,432		3,015		6,786		5,798
Depreciation and amortization – Total segments		7,757		6,388		15,131		12,614
Depreciation and amortization – Corporate		391		453		798		918
Corporate costs		10,491		9,918		20,219		18,804
Restructure costs		—		—		425		—
Stock-based compensation		564		564		1,129		1,129
Acquisition-related cost of goods sold		—		—		280		—
Acquisition-related transaction costs		—		—		462		—
Acquisition-related other		167		—		167		—
Other, net		—		(1,506)		—		(1,506)
Foreign currency (gains) losses, net		(718)		2,617		2,503		(18)
Adjusted EBITDA – Total segments	$	38,979	$	41,523	$	68,367	$	80,518


	December 31,		June 30,
As of	2019		2019
Identifiable assets
Animal Health	$	572,921	$	508,864
Mineral Nutrition		69,988		67,662
Performance Products		33,530		32,886
Total segments		676,439		609,412
Corporate		111,879		117,259
Total	$	788,318	$	726,671

Derivatives (Tables)

Schedule of significant outstanding derivatives employed to manage market risk and designated as cash flow hedges

Derivatives


		Notional			Asset (Liability)
		Amount at			fair value as of
		December 31,		Consolidated	December 31,		June 30,
Instrument	Hedge	2019		Balance Sheet	2019		2019
Options	Brazilian Real calls	R$	108,000	(1)	$	659	$	413
Options	Brazilian Real puts	R$	108,000	(1)	$	(217)	$	(30)
Swap	Interest rate swap	$	150,000	Other liabilities	$	(1,040)	$	(977)

(1)

Schedule of consolidated statements of operations and other comprehensive income


											Consolidated Statement
						Gain (Loss) recognized in consolidated					of Operations Line
For the Three Months Ended December 31		Gain (Loss) recorded in OCI				statements of operations					Item Total
						Consolidated
						Statement of
Instrument	Hedge	2019		2018		Operations	2019		2018		2019		2018
Options	Brazilian Real calls	$	422	$	513	Cost of goods sold	$	(63)	$	—	$	144,908	$	149,579
Swap	Interest rate swap	$	658	$	(2,756)	Interest expense, net	$	—	$	—	$	3,432	$	3,015


											Consolidated Statement
						Gain (Loss) recognized in					of Operations Line
For the Six Months Ended December 31		Gain (Loss) recorded in OCI				consolidated statements of operations					Item Total
						Consolidated
						Statement
Instrument	Hedge	2019		2018		of Operations	2019		2018		2019		2018
Options	Brazilian Real calls	$	59	$	404	Cost of goods sold	$	(108)	$	1,084	$	276,965	$	283,927
Swap	Interest rate swap	$	(63)	$	(2,106)	Interest expense, net	$	—	$	—	$	6,786	$	5,798

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959

XML 45 R18.htm IDEA: XBRL DOCUMENT

Derivatives

XML 46 R14.htm IDEA: XBRL DOCUMENT

Derivatives

Derivatives

10. Derivatives

We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “—Fair Value Measurements.”

Outstanding derivatives that are designated and effective as cash flow hedges as of December 31, 2019 were:


		Notional			Asset (Liability)
		Amount at			fair value as of
		December 31,		Consolidated	December 31,		June 30,
Instrument	Hedge	2019		Balance Sheet	2019		2019
Options	Brazilian Real calls	R$	108,000	(1)	$	659	$	413
Options	Brazilian Real puts	R$	108,000	(1)	$	(217)	$	(30)
Swap	Interest rate swap	$	150,000	Other liabilities	$	(1,040)	$	(977)

(1)

The following tables show the effects of derivatives on the consolidated statements of operations and other comprehensive income for the three and six months ended December 31, 2019 and 2018.


											Consolidated Statement
						Gain (Loss) recognized in consolidated					of Operations Line
For the Three Months Ended December 31		Gain (Loss) recorded in OCI				statements of operations					Item Total
						Consolidated
						Statement of
Instrument	Hedge	2019		2018		Operations	2019		2018		2019		2018
Options	Brazilian Real calls	$	422	$	513	Cost of goods sold	$	(63)	$	—	$	144,908	$	149,579
Swap	Interest rate swap	$	658	$	(2,756)	Interest expense, net	$	—	$	—	$	3,432	$	3,015


											Consolidated Statement
						Gain (Loss) recognized in					of Operations Line
For the Six Months Ended December 31		Gain (Loss) recorded in OCI				consolidated statements of operations					Item Total
						Consolidated
						Statement
Instrument	Hedge	2019		2018		of Operations	2019		2018		2019		2018
Options	Brazilian Real calls	$	59	$	404	Cost of goods sold	$	(108)	$	1,084	$	276,965	$	283,927
Swap	Interest rate swap	$	(63)	$	(2,106)	Interest expense, net	$	—	$	—	$	6,786	$	5,798

We recognize gains (losses) related to foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold.

Debt

XML 47 R10.htm IDEA: XBRL DOCUMENT

Debt

Debt

6. Debt

Term Loans and Revolving Credit Facilities

Long-Term Debt


	December 31,		June 30,
As of	2019		2019
Term A Loan due June 2022	$	225,000	$	231,250
Other		—		40
		225,000		231,290
Unamortized debt issuance costs and debt discount		(929)		(1,115)
		224,071		230,175
Less: current maturities		(15,625)		(12,540)
	$	208,446	$	217,635

Summary of Significant Accounting Policies and New Accounting Standards

Summary of Significant Accounting Policies and New Accounting Standards

Summary of Significant Accounting Policies and New Accounting Standards

2. Summary of Significant Accounting Policies and New Accounting Standards

Leases

Net Income per Share and Weighted Average Shares

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Net income	$	11,894	$	14,748	$	14,409	$	31,062
Weighted average number of shares – basic		40,454		40,383		40,454		40,376
Dilutive effect of stock options and restricted stock units		50		140		50		147
Weighted average number of shares – diluted		40,504		40,523		40,504		40,523
Net income per share
basic	$	0.29	$	0.37	$	0.36	$	0.77
diluted	$	0.29	$	0.36	$	0.36	$	0.77

New Accounting Standards

XML 48 R33.htm IDEA: XBRL DOCUMENT

Acquisition - Acquired Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Aug. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
The preliminary fair values of the acquired assets and liabilities as of the acquisition date
Goodwill	$ 52,679		$ 27,348	$ 27,348
Osprey Biotechnics, Inc. ("Osprey")
The preliminary fair values of the acquired assets and liabilities as of the acquisition date
Working capital, net		$ 2,366
Property, plant and equipment		2,005
Definite-lived intangible assets		32,400
Goodwill		25,331
Net assets acquired		$ 62,102

XML 49 R37.htm IDEA: XBRL DOCUMENT

Statements of Operations - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Statements Of Operations Additional Information [Line Items]
Deferred revenue	$ 5,130	$ 5,464
Current deferred revenue, included in accrued expense and other current liabilities	$ 1,082	$ 965
Customer \| Maximum
Statements Of Operations Additional Information [Line Items]
Payment term	120 days
Average worldwide collection period for accounts receivable	70 days
Customer \| Minimum
Statements Of Operations Additional Information [Line Items]
Payment term	30 days
Average worldwide collection period for accounts receivable	60 days

XML 50 R56.htm IDEA: XBRL DOCUMENT

Business Segments - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Equity method investments
Equity method investments	$ 4,902	$ 4,196
Animal Health
Equity method investments
Equity method investments	3,548	3,287
Performance Products
Equity method investments
Equity method investments	$ 852	$ 759

XML 51 R52.htm IDEA: XBRL DOCUMENT

Derivatives - Additional Information (Details) - USD ($)	6 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jul. 31, 2017
Derivative [Line Items]
Maximum maturity period for Foreign Currency Derivatives	Jun. 30, 2021
Other Current Assets
Derivative [Line Items]
Fair values of total foreign currency derivatives outstanding	$ 442	$ 383
Interest Rate Swap
Derivative [Line Items]
Derivative, Notional Amount	$ 150,000		$ 150,000
Percentage of interest rate	1.8325%

XML 52 R43.htm IDEA: XBRL DOCUMENT

Leases - ROU assets and the related lease liabilities (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Leases
Remaining non-cancelable lease terms	16 years
Operating lease ROU assets included in Other Assets	$ 23,115
Operating lease ROU assets included in Other Assets	us-gaap:OtherAssetsNoncurrent
Current portion included in Accrued expenses and other current liabilities	$ 6,672
Current portion included in Accrued expenses and other current liabilities	us-gaap:AccruedLiabilitiesCurrent
Non-current portion included in Other liabilities	$ 17,453
Non-current portion included in Other liabilities	us-gaap:OtherLiabilitiesNoncurrent
Total operating lease liabilities	$ 24,125

XML 53 R47.htm IDEA: XBRL DOCUMENT

Leases - Future minimum lease payments for operating leases accounted for under ASC 840 (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Leases
2020	$ 5,815
2021	4,160
2022	3,191
2023	1,445
2024	865
Thereafter	765
Total minimum lease payments	$ 16,241

XML 54 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	16,000,000	16,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock-Class A
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	20,287,574	20,287,574
Common stock, shares outstanding	20,287,574	20,287,574
Common stock-Class B
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	20,166,034	20,166,034
Common stock, shares outstanding	20,166,034	20,166,034

XML 55 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Dec. 31, 2019	Jan. 28, 2020
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Entity Registrant Name	PHIBRO ANIMAL HEALTH CORP
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Shell Company	false
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001069899
Amendment Flag	false
Trading Symbol	pahc
Common stock-Class A
Entity Common Stock, Shares Outstanding		20,287,574
Common stock-Class B
Entity Common Stock, Shares Outstanding		20,166,034

XML 56 R9.htm IDEA: XBRL DOCUMENT

Description of Business	6 Months Ended
Description of Business	Dec. 31, 2019
Description of Business
Description of Business	1. Description of Business Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, dairy and beef cattle, and aquaculture. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries. The unaudited consolidated financial information for the three and six months ended December 31, 2019 and 2018, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10‑K for the fiscal year ended June 30, 2019 (the “Annual Report”), filed with the Securities and Exchange Commission on August 27, 2019 (File no. 001‑36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of the financial position, results of operations and cash flows of the Company for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2019, was derived from the audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report. The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated from the consolidated financial statements. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.

XML 57 R26.htm IDEA: XBRL DOCUMENT

Debt (Tables)

Schedule of long term debt

Debt


	December 31,		June 30,
As of	2019		2019
Term A Loan due June 2022	$	225,000	$	231,250
Other		—		40
		225,000		231,290
Unamortized debt issuance costs and debt discount		(929)		(1,115)
		224,071		230,175
Less: current maturities		(15,625)		(12,540)
	$	208,446	$	217,635

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

XML 58 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and New Accounting Standards (Tables)

Summary of Significant Accounting Policies and New Accounting Standards

Schedule of net income per share and weighted average shares


	Three Months				Six Months
For the Periods Ended December 31	2019		2018		2019		2018
Net income	$	11,894	$	14,748	$	14,409	$	31,062
Weighted average number of shares – basic		40,454		40,383		40,454		40,376
Dilutive effect of stock options and restricted stock units		50		140		50		147
Weighted average number of shares – diluted		40,504		40,523		40,504		40,523
Net income per share
basic	$	0.29	$	0.37	$	0.36	$	0.77
diluted	$	0.29	$	0.36	$	0.36	$	0.77

XML 59 R42.htm IDEA: XBRL DOCUMENT

Debt - Additional Information (Details) - USD ($)	6 Months Ended
Debt - Additional Information (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jul. 31, 2017
Debt Instrument [Line Items]
Revolving credit facility	$ 149,000,000	$ 96,000,000
Interest Rate Swap
Debt Instrument [Line Items]
Percentage of interest rate				1.8325%
Derivative, Notional Amount	150,000			$ 150,000
Credit Agreement [Member] \| Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity	250,000,000
Revolving credit facility	149,000,000
Outstanding letters of credit	2,709,000
Aggregate available credit facilities	$ 98,291,000
Weighted-average interest rates	3.58%		3.71%
Percentage of interest rate	3.51%
Credit Agreement [Member] \| Term A Loans And Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maturity dates	June 29, 2022
Covenant requirement, permitted leverage ratio	a maximum First Lien Net Leverage Ratio and (ii) a minimum consolidated interest coverage ratio, each calculated on a trailing four quarter basis
Debt instrument, covenant compliance	we were in compliance with the financial covenants
Credit Agreement [Member] \| Term A Loans And Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest rate, description	2.00%, 1.75% or 1.50%
Floor rate	0.00%
Credit Agreement [Member] \| Term A Loans And Revolving Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Interest rate, description	2.00%, 1.75% or 1.50%
Credit Agreement [Member] \| Term A Loans And Revolving Credit Facility [Member] \| Base Rate
Debt Instrument [Line Items]
Interest rate, description	1.00%, 0.75% or 0.50%
Credit Agreement [Member] \| Term A Loan [Member]
Debt Instrument [Line Items]
Aggregate principal amount	$ 250,000,000
Weighted-average interest rates	3.46%		3.47%
Percentage of interest rate	3.61%

XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 R46.htm IDEA: XBRL DOCUMENT

Leases - Maturities of future lease liabilities (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Leases
2020	$ 3,853
2021	6,627
2022	5,012
2023	2,765
2024	2,283
2025 and thereafter	7,273
Total lease payments	27,813
Less: interest	3,688
Total operating lease liabilities	$ 24,125

XML 62 R8.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parentheticals) - $ / shares	3 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
Dividends declared per share	$ 0.12	$ 0.12	$ 0.12	$ 0.10

XML 63 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
ASSETS
Cash and cash equivalents	$ 26,180	$ 57,573
Short-term investments	49,000	24,000
Accounts receivable, net	147,441	159,022
Inventories, net	193,509	198,322
Other current assets	29,357	27,245
Total current assets	445,487	466,162
Property, plant and equipment, net	144,733	140,235
Intangibles, net	75,541	47,478
Goodwill	52,679	27,348
Other assets	69,878	45,448
Total assets	788,318	726,671
LIABILITIES AND STOCKHOLDERS' EQUITY
Current portion of long-term debt	15,625	12,540
Accounts payable	58,263	73,189
Accrued expenses and other current liabilities	73,171	68,498
Total current liabilities	147,059	154,227
Revolving credit facility	149,000	96,000
Long-term debt	208,446	217,635
Other liabilities	66,398	42,794
Total liabilities	570,903	510,656
Commitments and contingencies (Note 9)
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,287,574 shares issued and outstanding at December 31, 2019 and June 30, 2019; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at December 31, 2019 and June 30, 2019	4	4
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding
Paid-in capital	134,395	133,266
Retained earnings	173,626	168,926
Accumulated other comprehensive income (loss)	(90,610)	(86,181)
Total stockholders' equity	217,415	216,015
Total liabilities and stockholders' equity	$ 788,318	$ 726,671

XML 65 R27.htm IDEA: XBRL DOCUMENT

Leases (Tables)

Summary of the ROU assets and the related lease liabilities recorded on the consolidated balance sheet

Leases

The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:


	December 31,
As of	2019		Balance Sheet Classification
Assets:
Operating lease ROU assets	$	23,115	Other Assets

Liabilities:
Current portion		6,672	Accrued expenses and other current liabilities
Non-current portion		17,453	Other liabilities
Total operating lease liabilities	$	24,125

Summary of the composition of net lease cost

The following table summarizes the composition of net lease cost:


	Three months		Six months
For the Periods Ended December 31	2019		2019

Operating lease expense	$	1,911	$	3,762
Variable lease expense		307		631
Short-term lease expense		214		417
Total lease cost	$	2,432	$	4,810

Summary of other supplemental information

The following tables include other supplemental information:


	Three months		Six months
For the Periods Ended December 31	2019		2019
Operating cash flows used for ROU operating leases	$	1,968	$	3,645
Right of use assets obtained in exchange for new operating lease liabilities	$	3,972	$	7,762


	As of
	December 31, 2019
Weighted average remaining lease term (in years) - ROU operating leases	6.4
Weighted average discount rate - ROU operating leases	4.17	%

Summary of maturities of future lease liabilities

At December 31, 2019, maturities of future lease liabilities were:


For the Years Ending June 30
2020	$	3,853
2021		6,627
2022		5,012
2023		2,765
2024		2,283
2025 and thereafter		7,273
Total lease payments		27,813
Less: interest		3,688
Total operating lease liabilities	$	24,125

Summary of future minimum lease payments for operating leases accounted for under ASC 840, "Leases," with remaining non-cancelable terms in excess of one year

Future minimum lease payments for operating leases accounted for under ASC 840, "Leases," with remaining non-cancelable terms in excess of one year at June 30, 2019 were:


For the Years Ending June 30
2020	$	5,815
2021		4,160
2022		3,191
2023		1,445
2024		865
Thereafter		765
Total minimum lease payments	$	16,241

XML 66 R23.htm IDEA: XBRL DOCUMENT

Acquisition (Tables)

Summary of preliminary fair values of the acquired assets and liabilities

Acquisition


Working capital, net	$	2,366
Property, plant and equipment		2,005
Definite-lived intangible assets		32,400
Goodwill		25,331
Net assets acquired	$	62,102

XML 67 R15.htm IDEA: XBRL DOCUMENT

Leases

XML 69 R11.htm IDEA: XBRL DOCUMENT

Leases

Leases

7. Leases

The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:


	December 31,
As of	2019		Balance Sheet Classification
Assets:
Operating lease ROU assets	$	23,115	Other Assets

Liabilities:
Current portion		6,672	Accrued expenses and other current liabilities
Non-current portion		17,453	Other liabilities
Total operating lease liabilities	$	24,125

The following table summarizes the composition of net lease cost:


	Three months		Six months
For the Periods Ended December 31	2019		2019

Operating lease expense	$	1,911	$	3,762
Variable lease expense		307		631
Short-term lease expense		214		417
Total lease cost	$	2,432	$	4,810

The following tables include other supplemental information:


	Three months		Six months
For the Periods Ended December 31	2019		2019
Operating cash flows used for ROU operating leases	$	1,968	$	3,645
Right of use assets obtained in exchange for new operating lease liabilities	$	3,972	$	7,762


	As of
	December 31, 2019
Weighted average remaining lease term (in years) - ROU operating leases	6.4
Weighted average discount rate - ROU operating leases	4.17	%

At December 31, 2019, maturities of future lease liabilities were:


For the Years Ending June 30
2020	$	3,853
2021		6,627
2022		5,012
2023		2,765
2024		2,283
2025 and thereafter		7,273
Total lease payments		27,813
Less: interest		3,688
Total operating lease liabilities	$	24,125

Future minimum lease payments for operating leases accounted for under ASC 840, "Leases," with remaining non-cancelable terms in excess of one year at June 30, 2019 were:


For the Years Ending June 30
2020	$	5,815
2021		4,160
2022		3,191
2023		1,445
2024		865
Thereafter		765
Total minimum lease payments	$	16,241

Acquisition